Literature DB >> 3443610

Determination of vancomycin related substances by gradient high-performance liquid chromatography.

E L Inman1.   

Abstract

A gradient high-performance liquid chromatographic method for the determination of vancomycin related substances is described. This method was developed to profile vancomycin, co-fermentation products, and degradation products. The resultant chromatograms confirm the multifactored nature of vancomycin, separating a number of peaks from the main component. The development of acceptable chromatographic performance is described, with the final method intended for use as a control assay. Quantitation of total related substances is made by comparing the relative area of the main peak to total peak area in a pair of chromatograms from a stock solution and a twenty-five fold dilution. A rapid-scan UV detector was used to demonstrate the similar spectral characteristics of the vancomycin related substances, confirming the validity of the relative area approach. Statistical method validation data are included, evaluating the use of this method for quantitative applications. Example applications demonstrate the effectiveness of this method.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3443610     DOI: 10.1016/s0021-9673(00)90066-9

Source DB:  PubMed          Journal:  J Chromatogr


  7 in total

1.  Activity and diffusion of LY333328 in experimental endocarditis due to vancomycin-resistant Enterococcus faecalis.

Authors:  A Saleh-Mghir; A Lefort; Y Petegnief; S Dautrey; J M Vallois; D Le Guludec; C Carbon; B Fantin
Journal:  Antimicrob Agents Chemother       Date:  1999-01       Impact factor: 5.191

2.  Efficacy of LY333328 against experimental methicillin-resistant Staphylococcus aureus endocarditis.

Authors:  G W Kaatz; S M Seo; J R Aeschlimann; H H Houlihan; R C Mercier; M J Rybak
Journal:  Antimicrob Agents Chemother       Date:  1998-04       Impact factor: 5.191

3.  Three structurally-related impurities in norvancomycin drug substance.

Authors:  Zhibo Jiang; Xuan Lei; Minghua Chen; Bingya Jiang; Linzhuan Wu; Xuexia Zhang; Zhihui Zheng; Xinxin Hu; Xuefu You; Shuyi Si; Lifei Wang; Bin Hong
Journal:  J Antibiot (Tokyo)       Date:  2016-10-05       Impact factor: 2.649

4.  Inhibition of cell wall turnover and autolysis by vancomycin in a highly vancomycin-resistant mutant of Staphylococcus aureus.

Authors:  K Sieradzki; A Tomasz
Journal:  J Bacteriol       Date:  1997-04       Impact factor: 3.490

5.  Activity of LY333328 combined with gentamicin in vitro and in rabbit experimental endocarditis due to vancomycin-susceptible or -resistant Enterococcus faecalis.

Authors:  A Lefort; A Saleh-Mghir; L Garry; C Carbon; B Fantin
Journal:  Antimicrob Agents Chemother       Date:  2000-11       Impact factor: 5.191

6.  Experimental study of LY333328 (oritavancin), alone and in combination, in therapy of cephalosporin-resistant pneumococcal meningitis.

Authors:  Carmen Cabellos; Antonio Fernàndez; Jose M Maiques; Fe Tubau; Carmen Ardanuy; Pedro F Viladrich; Josefina Liñares; Francesc Gudiol
Journal:  Antimicrob Agents Chemother       Date:  2003-06       Impact factor: 5.191

7.  Oritavancin Pharmacokinetics and Bone Penetration in Rabbits.

Authors:  Dario Lehoux; Valerie Ostiguy; Cordelia Cadieux; Mireille Malouin; Odette Belanger; Adel Rafai Far; Thomas R Parr
Journal:  Antimicrob Agents Chemother       Date:  2015-08-03       Impact factor: 5.191

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.